Literature DB >> 1546744

Induction in mice of human light-chain-associated amyloidosis.

A Solomon1, D T Weiss, M B Pepys.   

Abstract

Primary (idiopathic) or multiple myeloma-associated amyloidosis is characterized by the deposition in tissue of monoclonal light chains or light-chain fragments (AL amyloidosis). In contrast to other types of amyloidosis, information regarding the pathogenesis of light-chain-related amyloid has heretofore been limited due to the lack of a suitable in vivo model. The authors report the successful experimental induction of human AL amyloid deposits. The repeated injection into mice of Bence Jones proteins obtained from two patients with AL amyloidosis produced the histopathologic lesions characteristic of this disease. Partial dehydration of animals before protein injection resulted in the acceleration of amyloid formation. The human proteins were deposited as amyloid within the mouse renal blood vessel walls and parenchymal tissue, as well as in other organs. The deposits were Congo red-positive, exhibited green birefringence, and had a fibrillar ultrastructure. As evidenced immunohistochemically, the experimentally induced amyloid deposits consisted of the injected human light chains, and in addition, contained mouse amyloid P component (AP); mouse immunoglobulin (Ig) or inflammatory-associated amyloid A protein was not detected. Extraction and characterization of the amyloid deposits found within the mouse kidney revealed the presence of a predominantly intact human light polypeptide chain. Mice injected in identical manner with a non-amyloid-associated Bence Jones protein had no or only rare amyloid deposits. The experimental mouse model provides a means to ascertain the amyloidogenic potential of human monoclonal light chains and to study further the pathogenesis of AL amyloidosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1546744      PMCID: PMC1886151     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  MULTIPLE MYELOMA I. THE PATHOGENESIS OF "AMYLOIDOSIS.

Authors:  E F OSSERMAN; K TAKATSUKI; N TALAL
Journal:  Semin Hematol       Date:  1964-01       Impact factor: 3.851

Review 2.  Amyloidosis: a final common pathway for protein deposition in tissues.

Authors:  M J Stone
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

3.  Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity.

Authors:  V Bellotti; G Merlini; E Bucciarelli; V Perfetti; S Quaglini; E Ascari
Journal:  Br J Haematol       Date:  1990-01       Impact factor: 6.998

4.  Amyloidosis related to a lambda IV immunoglobulin light chain protein.

Authors:  M D Benson; F E Dwulet; D Madura; G Wheeler
Journal:  Scand J Immunol       Date:  1989-02       Impact factor: 3.487

5.  Creation of "amyloid" fibrils from Bence Jones proteins in vitro.

Authors:  G G Glenner; D Ein; E D Eanes; H A Bladen; W Terry; D L Page
Journal:  Science       Date:  1971-11-12       Impact factor: 47.728

Review 6.  Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts).

Authors:  G G Glenner
Journal:  N Engl J Med       Date:  1980-06-05       Impact factor: 91.245

7.  Kinetics of amyloid deposition. I. The effects of amyloid-enhancing factor and splenectomy.

Authors:  R Kisilevsky; L Boudreau
Journal:  Lab Invest       Date:  1983-01       Impact factor: 5.662

8.  Further characterization of amyloid-enhancing factor.

Authors:  M A Axelrad; R Kisilevsky; J Willmer; S J Chen; M Skinner
Journal:  Lab Invest       Date:  1982-08       Impact factor: 5.662

9.  Pathologic conditions associated with plasma cell dyscrasias: a study of 806 cases.

Authors:  T Isobe; E F Osserman
Journal:  Ann N Y Acad Sci       Date:  1971-12-31       Impact factor: 5.691

10.  Isolation of serum amyloid P-component (protein SAP) in the mouse.

Authors:  M B Pepys
Journal:  Immunology       Date:  1979-07       Impact factor: 7.397

View more
  14 in total

1.  Structural relationship of kappa-type light chains with AL amyloidosis: multiple deletions found in a VkappaIV protein.

Authors:  M A Alim; S Yamaki; M S Hossain; K Takeda; M Kozima; T Izumi; I Takashi; T Shinoda
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  The effect of membranes on the in vitro fibrillation of an amyloidogenic light-chain variable-domain SMA.

Authors:  Xiaoyun Meng; Anthony L Fink; Vladimir N Uversky
Journal:  J Mol Biol       Date:  2008-06-28       Impact factor: 5.469

Review 3.  Molecular anatomy and the pathological expression of antibody light chains.

Authors:  M Schiffer
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

Review 4.  Amyloid Cardiomyopathy: Disease on the Rise.

Authors:  Ronglih Liao; Jennifer E Ward
Journal:  Circ Res       Date:  2017-06-09       Impact factor: 17.367

5.  Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain.

Authors:  Christina B Cooley; Lisa M Ryno; Lars Plate; Gareth J Morgan; John D Hulleman; Jeffery W Kelly; R Luke Wiseman
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-25       Impact factor: 11.205

6.  Macrophage-Mediated Phagocytosis and Dissolution of Amyloid-Like Fibrils in Mice, Monitored by Optical Imaging.

Authors:  Tina Richey; James S Foster; Angela D Williams; Anna B Williams; Alexa Stroh; Sallie Macy; Craig Wooliver; R Eric Heidel; Siva K Varanasi; Elizabeth N Ergen; Dianne J Trent; Stephen A Kania; Stephen J Kennel; Emily B Martin; Jonathan S Wall
Journal:  Am J Pathol       Date:  2019-02-06       Impact factor: 4.307

7.  Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.

Authors:  Bonnie K Arendt; Marina Ramirez-Alvarado; Laura A Sikkink; Jonathan J Keats; Gregory J Ahmann; Angela Dispenzieri; Rafael Fonseca; Rhett P Ketterling; Ryan A Knudson; Erin M Mulvihill; Renee C Tschumper; Xiaosheng Wu; Steven R Zeldenrust; Diane F Jelinek
Journal:  Blood       Date:  2008-06-20       Impact factor: 22.113

8.  Light chain-associated amyloid deposits comprised of a novel kappa constant domain.

Authors:  A Solomon; D T Weiss; C L Murphy; R Hrncic; J S Wall; M Schell
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 9.  Primary systemic amyloidosis.

Authors:  Morie A Gertz; S Vincent Rajkumar
Journal:  Curr Treat Options Oncol       Date:  2002-06

Review 10.  Animal models of monoclonal immunoglobulin-related renal diseases.

Authors:  Christophe Sirac; Guillermo A Herrera; Paul W Sanders; Vecihi Batuman; Sebastien Bender; Maria V Ayala; Vincent Javaugue; Jiamin Teng; Elba A Turbat-Herrera; Michel Cogné; Guy Touchard; Nelson Leung; Frank Bridoux
Journal:  Nat Rev Nephrol       Date:  2018-02-19       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.